NICE aims to cut funding for Amgen lung cancer drug Lumykras
From the article
NICE aims to cut funding for Amgen lung cancer drug Lumykras Phil.Taylor Thu, 09/07/2026 - 10:34
Continue reading on pharmaphorumYou might also wanna read
NICE refuses funding for advanced breast cancer treatment, Tyverb® (lapatinib)
GSK·17y ago
New cancer drug trial offers hope for patients with rare aggressive tumour
Reading Chronicle·2d ago
Conquer Cancer, the ASCO Foundation Opens Applications for Lung Cancer Quality Improvement Grants
OncoDaily·1d ago
A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)
clinicaltrials.gov·7d ago
Cancer therapies in 2026: a new era of hope
مجلة المجلة | مجلة العرب الدولية·2d ago
A turning point for pancreatic cancer patients
statnews.com·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.